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Context Randomised controlled trials in non-alcoholic fatty liver disease (NAFLD) have shown that
regular exercise, even without calorie restriction, reduces liver steatosis. A previous study has
shown that 16 weeks supervised exercise training in NAFLD did not affect total VLDL kinetics.
Objective: To determine the effect of exercise training on intrahepatocellular fat (IHCL) and the
kinetics of large triglyceride-(TG)-rich VLDL1 and smaller denser VLDL2 which has a lower TG
content.
Design A 16 week randomised controlled trial.
Patients 27 sedentary patients with NAFLD.
Intervention Supervisedexercisewithmoderate-intensity aerobic exerciseor conventional lifestyle
advice (control).
Main outcome Very low density lipoprotein1 (VLDL1) and VLDL2-TG and apolipoproteinB (apoB)
kinetics investigated using stable isotopes before and after the intervention.
Results: In the exercise group VO2max increased by 316% (meanSEM) and IHCL decreased from
19.6% (14.8, 30.0) to 8.9% (5.4, 17.3) (median (IQR)) with no significant change in VO2max or IHCL
in the control group (change betweengroups p0.001 andp0.02, respectively). Exercise training
increased VLDL1-TG and apoB fractional catabolic rates, a measure of clearance, (change between
groups p0.02 and p0.01, respectively), and VLDL1-apoB production rate (change between
groups p0.006),with no change inVLDL1 -TGproduction rate. Plasma TGdid not change in either
group.
Conclusion:An increased clearance of VLDL1may contribute to the significant decrease in liver fat
following 16 weeks of exercise in NAFLD. A longer duration or higher intensity exercise interven-
tions may be needed to lower plasma TG and VLDL production rate.
NAFLD, the most prevalent liver disease in the devel-oped world (1), increases the risk of chronic liver
disease, hepatocellular carcinoma and cardiovascular dis-
ease, and is associated with increased visceral fat, hyper-
triglyceridaemia and insulin resistance (2).
Hepatic steatosis is the result of an imbalance between
triglyceride (TG) synthesis andTGexport. TGs stored and
secreted by the liver are synthesized from fatty acids gen-
erated from three main sources: hepatic de novo lipogen-
esis; circulating nonesterified fatty acids (NEFA), origi-
nating from adipose tissue; and fatty acids derived from
the remnants of the TG rich lipoproteins, VLDL and chy-
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
Copyright © 2016 by the Endocrine Society
Received June 9, 2016. Accepted August 17, 2016.
Abbreviations:
O R I G I N A L A R T I C L E
doi: 10.1210/jc.2016-2353 J Clin Endocrinol Metab press.endocrine.org/journal/jcem 1
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 09 September 2016. at 00:05 For personal use only. No other uses without permission. . All rights reserved.
lomicrons (3)whichare generatedwhen these lipoproteins
are cleared from the circulation by the lipolytic action of
lipoprotein lipase (LPL) and hepatic lipase (4).
VLDL secreted by the liver can be separated into large
TG-rich VLDL1 and smaller denser VLDL2 which has a
lower TG content. There is evidence that these two VLDL
species are independently regulated (5). VLDL is initially
assembled as a primordial particle (pre-VLDL)when apo-
lipoprotein B100 (apoB) is cotranslationally lipidated in
the endoplasmic reticulumbymicrosomal transfer protein
(MTP). Pre-VLDL can either be retained and degraded, or
further lipidated to form VLDL2.This particlecan then ei-
ther be secreted or converted to VLDL1 following the ad-
dition of more TG in the liver. The hydrolysis of
VLDL1-TG by lipoprotein lipase (LPL) also generates
VLDL2 in the circulation. Thus VLDL2 has two sources.
Insulin regulates VLDL assembly by decreasing apoB
mRNA translation (6), inhibiting the expression of MTP
(7) andpromoting apoBdegradation via autophagy (8). In
NAFLD, with intrahepatic lipids in copious supply, in-
creases in both VLDL-apoB and VLDL-TG production
rate (PR) contribute to the atherogenic lipid profile (9).
Lifestyle intervention is the first line of treatment for
NAFLD. Weight loss (5%–10%) through diet, with or
without exercise, has been shown to reduce hepatic ste-
atosis (10, 11). A number of randomized controlled trials
have also shown that regular exercise, even without cal-
orie restriction, reduces liver steatosis (12, 13). A previous
study has shown that 16 weeks supervised exercise train-
ing in men and women with NAFLD did not affect total
VLDL kinetics (14). In the current study we examined the
effect of 16weeks supervised exercise training inmenwith
NAFLD on VLDL1 and VLDL2 kinetics, using a protocol
which we have shown previously to very effective at in-
creasing fitness (15).
Materials and Methods
Study design. The study was approved by the English National
Health Service (NHS) Ethics Committee and the University of
Surrey Ethics Committee. The study was performed at one cen-
ter, in Guildford, Surrey. This study is part of a larger collabor-
ative study investigating the metabolic impact of exercise super-
vision in patients with NAFLD (16). Informed consent was
obtained from the study participants prior to inclusion into the
study.
Study participants. Twenty nine sedentary male patients, con-
firmed to have NAFLDwere recruited through the English NHS
primary and secondary care providers in the local area. There
were two dropouts, one in each group. Twenty seven patients
completed the study (Table 1) The diagnosis of NAFLD was
made in patients who had been referred for investigation of
raised serum transaminases, indication of hepatic steatosis on
ultrasound or by liver biopsy (n 4, two in each group; none of
these patients had nonalcoholic steatohepatitis). It was not pos-
sible to exclude NASH from subjects who were not recruited by
biopsy. Patients were excluded if the diagnosis of NAFLD was
secondary to drug treatments, if there was evidence of viral hep-
atitis, autoimmune hepatitis or primary biliary cirrhosis, or met-
abolic disorders, if they had a history of type 2 diabetes mellitus,
ischemic heart disease or had any contraindications to exercise,
clinical hyperlipidemia (fasting plasmaTG 3.0mmol/l or total
cholesterol levels  7.0 mmol/l), if they were current smokers,
had a history of excessive alcohol intake (weekly consumption
of  21 U), had MRI contraindications (cardiac pacemakers,
metal implants), or were taking any fibrates or beta blockers.
Participantswere asked to complete a Physical ActivityRead-
iness Questionnaire to identify those not suitable for physical
activity. Motivation was assessed through questions relating to
willingness to increase exercise levels and confidence in comply-
ing with exercising four times per week. Suitable participants
were randomized to one of two groups using a list generated by
computer randomisation, (Statistical Analysis System (SAS) v
9.1, PROC PLAN software). One group received a structured
supervised exercise program with an exercise physiologist. The
other group received standard lifestyle advice (control group)
Table 1. Subject characteristics and biochemistry
Pre Ex
n  15
Post Ex
n  15
Within group
p value
Pre Control
n  12
Post Control
n  12
Within group
p value
Between group
p value
Age yr 52.4 .2.2 52.8  3.0 NS
Body weight kg 101.3  2.64 97.3  12.2 <0.001 102.3  6.1 102.9  6.4 NS <0.001
BMI kg/m2 31.6  0.8 30.5  1.0 <0.001 31.7  1.0 31.6  1.2 NS 0.02
Waist circumference cm 109.3  1.9 105.0  2.5 0.005 110.0  3.9 109.6  4.3 NS 0.03
VO2max ml kg
-1 min-1 25.5  1.1 33.0  1.5 <0.001 23.3  1.0 23.8  1.3 NS <0.001
Fasting glucose mmol/liter 6.0  0.2 5.8  0.2 0.005 5.9  0.2 5.6  0.1 0.02 NS
Fasting insulin pmol/liter 183  17 138  16 0.007 164  17 170  17 NS 0.02
HOMA2%S 32.5  2.9 45.6  4.9 0.002 36.1  3.7 34.5  3.2 NS 0.003
Adipose tissue-IR 79.8  8.0 58.2  8.8 0.03 75.9  9.4 86.6  15.7 NS 0.02
NEFA mmol/liter 0.45  0.03 0.41  0.04 NS 0.48  0.05 0.50  0.05 NS NS
Total Cholesterol mmol/liter 5.0  0.2 4.7  0.2 NS 5.1  0.2 5.1  0.2 NS NS
TG mmol/liter 2.0  0.2 1.8  0.2 NS 1.6  0.2 1.9  0.2 NS NS
LDL-Cholesterol mmol/liter 3.8  0.1 3.3  0.2 0.03 3.6  0.2 3.2  0.2 0.07 NS
HDL-Cholesterol (mmol/liter 1.01  0.06 1.03  0.06 NS 1.09  0.09 1.09  0.08 NS NS
Alanine transaminase U/liter 51.1  5.3 36.8  5.2 0.01 40.9  6.2 31.1  4.7 0.04 NS
Aspartate transaminase U/liter 36.9  3.2 29.4  3.5 0.02 29.0  2.5 26.3  1.84 NS NS
 glutamyl transaminase U/liter 53.5  10.2 36.3  7.5 0.03 37.0  4.5 33.8  4.9 NS NS
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with no further communication from the exercise physiologist.
Both groups were asked to continue their usual diet.
Study measurements. Prior to and following the 16 week inter-
vention period measurements of physical fitness (VO2max) were
made and a 7 day diet diary was completed. On a separate visit,
measurements of fasting VLDL1 and VLDL2-apoB and TG ki-
netics and arterial stiffness (by pulse wave velocity) were made.
Body composition (total, subcutaneous and visceral fat volumes)
wasmeasured bymagnetic resonance imaging (MRI) and IHCL,
intramyocellular (IMCL) and pancreatic lipid content was mea-
sured by magnetic resonance spectroscopy (1H-MRS).
Physical training protocol. Participants allocated to the super-
vised group exercised at moderate intensity (40%–60% heart
rate reserve) for 20minutes initially (progressing towards 1 hour
as the program developed) 4–5 times per week for 16 weeks.
Types of activities were either gym based aerobic plus resistance
exercise, or outdoor aerobic activities and resistance exercise as
discussed with the exercise physiologist. Participants received
weekly exercise supervision by the exercise physiologist usually
in person, otherwise by telephone, to assess their progress.
Measurement of VO2max. VO2max was performed within four
daysof themetabolic studyusinganelectronicallybrakedbicycle
ergometer (Lode; Excalibur Sport, Groningen, the Netherlands)
equipped with a computerised breath (oxygen [O2]/carbon di-
oxide [CO2]) analyzer system (Medical Graphics, St Paul, MN,
USA). An electrocardiogram (ECG) was undertaken during the
exercise test to monitor participants’ heart rate and exclude la-
tent ischemic heart disease.
Measurement of pulse wave velocity is described
in the Supplementary Material.
Diet diaries. Quantification of dietary intake in all participants
was assessed by diet diary, and analyzed by Dietplan 6 (Release
6.60b4withWindows VistaService Pack 1. Forestfield Software
Ltd, Horsham, West Sussex, UK).
Measurement of body composition and intracellular fat. Sub-
jects fasted for 6 hours before the scans. Whole body MR im-
aging for body fat content and 1H MRS measurements of pan-
creatic fat, IHCL and IMCL (tibialis anterior and soleus muscle)
was measured on an Intera 1.5T Achieva multinuclear system
(Philips Medical Systems, Best, Holland) as previously reported
(17, 18). NAFLDwas defined as mean IHCL 55%. For more
details see the Supplementary Material.
Metabolic Study Protocol. Participants attended the CEDAR
center, Royal Surrey County Hospital, Guildford on two occa-
sions before (0 week) and after the intervention (16 weeks). The
participantswere asked to refrain fromvigorous exercise for 72h
before the study, abstain from drinking alcoholic beverages for
24h, and attend after an overnight fast. A primed (1 mg/kg)
intravenous (IV) infusion of 1-13C-leucine (1 mg/kg/h) and a
bolus of 2H5 glycerol (75 mol/kg) were administered. Blood
samples were taken at regular time intervals for 9 hours.
Laboratory protocols.VLDL1 (Svedberg flotation rate 60–400)
and VLDL2 (Svedberg flotation rate 20–60) fractions were iso-
lated from plasma by sequential ultracentrifugation (19). ApoB
and TG were isolated from VLDL1 and VLDL2 hydrolyzed, de-
rivatised and isotopic enrichment measured by gas chromatog-
raphymass spectrometry as described in the SupplementaryMa-
terial. Concentration measurements are also described in the
Supplementary Material.
Power calculation. The primary endpoint for this study was
VLDL-apoB production rate. Based on a previous study in type
2 diabetes where a 6 month exercise program reduced VLDL-
apoB production rate by 48% (20), the study was powered to
detect a 20%within-group reduction inVLDL-apoBproduction
with 80% power at the 5% level.
Data analysis. Themeasurements of enrichment of free glycerol
in plasma and glycerol enrichment of TG in VLDL1 and VLDL2
particles were used to determine VLDL1 and VLDL2-TG frac-
tional catabolic rate (FCR) using the modeling software SAAM
II (SAAM Institute, Seattle, WA) as previously described (23).
The model was also used to determine the kinetic parameters of
VLDL1 and VLDL2 apoB using plasma KIC enrichment and
1-13C leucine enrichment of VLDL1 and VLDL2-apoB.
VLDL1-TG and apoB FCR had two components, VLDL1 FCR
transfer (toVLDL2) andVLDL1FCRcatabolism (direct removal
from circulation). Production rate (PR) was calculated as the
product of VLDL1 and VLDL2-FCR and their respective pool
sizes. VLDL1 and VLDL2-TG and apoB pool sizes were calcu-
lated from VLDL1 and VLDL2-TG and apoB concentrations in
ultracentrifugation fractions and plasma volume as previously
described (21). (For more details of the models see the Supple-
mentaryMaterial). Total VLDL-TG and VLDL-apoB pool sizes
were calculated by the addition of VLDL1 and VLDL2-TG and
apoB pool sizes respectively. Particle sizes of VLDL1 andVLDL2
were calculated bydividingTGpool size by apoBpool size. Total
VLDL-TG PR was calculated by summation of VLDL1-TG PR
and VLDL2-TG hepatic PR.
Ten-year cardiovascular riskwas calculated using the 10 year
FraminghamRisk Score (FRS) (22). HomeostaticModel Assess-
ment (HOMA2)wasused toassesswholebody insulin sensitivity
(HOMA2-%S) (23).Adipose tissue insulin resistance (Adipo-IR)
was calculated by multiplying fasting plasma NEFA concentra-
tion with fasting serum insulin concentration.
Percent Change in IHCLwas calculated as Pre-Post interven-
tion/Pre x100. Changes in other measurements were calculated
as Pre-Post intervention.
Statistical analysis. Statistical analysis of the data was per-
formed using SPSS version 21.0 for Window (Chicago: SPSS
Inc.). IHCL is shown as median (interquartile range). All other
results are means  SEM. Non parametric data was log-trans-
formed. Basal comparisons were performed using Student’s t
test.Within-group changes between baseline and 16weeks were
compared using paired t tests. The change between baseline and
16weekswas compared between groups using student’s t test for
parametric data and Mann-Whitney U test for nonparametric
data. Correlations were assessed by Pearson’s correlation coef-
ficient and Spearman’s rho correlation coefficient when the data
were not normally distributed. A p value  0.05 was taken as
statistically significant.
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Results
Baseline characteristics
Body weight, BMI and baseline biochemical character-
istics (plasma lipid profile and liver enzyme concentra-
tions) were not significantly different at 0 weeks between
groups (Table 1). Similarly, therewere no significant base-
line differences in cardiorespiratory fitness (VO2max),
IHCL, pancreatic fat or fat distribution (Table 2). IHCL in
all participants (n  27) at 0 week correlated positively
with fastingplasmaTGconcentration (r0.439,P .02)
and abdominal visceral fat (r  0.411, P  .03).
Effects of intervention (exercise training vs.
control)
Body weight, BMI and fitness
Body weight and BMI decreased by 3.6  0.8% and
3.8  0.9% respectively after 16 weeks exercise training
with no change in controls (change exercise vs. change
control P .001 and, P .02) (Table 1). In both groups,
total energy intake and macronutrient composition re-
mainedunchanged after 16weeks comparedwithbaseline
(Supplemental Table 1).
In the exercise groupVO2max increased significantly by
31  6% after 16 weeks with no change in controls
(change in exercise group vs. control, P .001) (Figure 1,
Table 1).
Liver enzymes (Table 1)
After 16 weeks intervention there were within group
decreases in the exercise group in ALT, AST and GGT
concentrations (P  .01, P  .02 and P  .03, respec-
tively). ALT also decreased in controls (P  .04) with no
change in either AST or GGT.
Body composition and ectopic fat (Table 2)
After 16 weeks, there was a significant decrease in
IHCL content (% decrease 52.2% (29.0, 61.8); median
(IQR)) in the exercise group, with no change in controls
(change exercise vs. change controlP .02). Therewas no
significant change in pancreatic fat. All measured adipose
tissue depots also significantly decreased with no change
in controls (Table 2). The percentage change in IHCL be-
tween 0 and 16 weeks in all patients (exercise and control
group) correlated negatively with the change in VO2max
(r-0.45, P  .02) and correlated positively with the
change in total body fat and visceral fat (; r  0.54, P 
.004; r  0.41, P  .03).
Insulin sensitivity, fasting plasma insulin and
glucose concentration (Table 1)
After 16 weeks exercise there was a within-group de-
crease in fasting plasma glucose and serum insulin con-
centrations in the exercise group (both P .01) (between
groups for insulin, P  .02). HOMA2-%S (a measure of
insulin sensitivity) increased by 42.5  11.6% in the ex-
ercise group (P  .002) with no change in controls (be-
tween group, P  .003).
Blood pressure, pulse wave velocity and
Framingham risk factor scores (Table 2)
Both systolic and diastolic blood pressure (BP) mea-
surements decreased by5.41.8%and6.22.7% in the
exercise group after 16 weeks exercise (P .01, P .04)
(between groups P  .04, P  .02 respectively). After 16
weeks, pulse wave velocity, a measure of atrial elasticity,
improved in the exercise group (P  .05) although be-
tween groups this was not significant. The Framingham
risk score decreased 14  4% (P  .001) after exercise
with no change in controls (between groups,P .05). The
percentage change in IHCL between 0 and 16 weeks in all
patients correlated positively with the change in the FRS
(r  0.62, P  .001).
Plasma and fraction lipids (Tables 1, 3 and 4)
At baseline, there were no differences in plasma or li-
poprotein fraction lipids between groups. Total choles-
Table 2. Body composition and vascular measurements
Pre Ex
n  15 Post Ex n  15 Within group p value Pre Control n  12 Post Control n  12 Within group p value Between group p value
IHCL % 19.6 (14.8,30.0) 8.9 (5.4,17.3) <0.001 12.5 (6.9,32.9) 12.6 (9.2,26.1) NS 0.02
IMCL (Sol) 21.7  3.8 19.0  3.5 0.09 19.2  1.8 20.5  2.6 NS 0.07
IMCL (Tib) 8.8  1.0 8.8  1.4 NS 13.2  5.4 8.2  1.2 NS NS
Pancreatic fat 13.7  5.0 8.8  1.6 NS 8.2  3.3 10.9  3.5 NS NS
Total Internal fat kg 9.5  0.6 7.9  0.6 <0.001 9.9  0.9 9.6  0.9 NS 0.03
Visceral Fat kg 5.7  0.4 4.7  0.4 <0.001 5.7  0.55 5.4  0.6 NS 0.06
Abdominal Subcut Fat kg 7.0  7.2 6.3  0.7 <0.001 7.8  1.0 7.91  1.1 NS 0.003
Total body fat kg 31.6  2.0 27.3  1.9 <0.001 34.8  3.2 34.5  3.5 NS 0.004
Total subcut fat kg 22.1  1.7 19.5  1.6 <0.001 24.9  2.4 24.9  2.6 NS 0.001
Systolic BP mm Hg 133.4  4.2 128.8  4.2 0.01 131.3  4.5 134.4  3.8 NS 0.04
Diastolic BP mm Hg 83.4  2.3 78.2  2.6 0.04 83.8  3.0 86.3  3.0 NS 0.02
PWV (m/s) 7.94  0.26 7.67  0.25 0.05 7.58  0.27 7.77  0.28 NS NS
Framingham Risk scores 14.4  1.4 12.4  1.4 0.001 14.2  2 .5 13.6  1.9 NS <0.05
Intrahepatocellular fat (IHCL) presented as median (interquartile range)
Sol, soleus; Tib, tibialis; visc, visceral; subcut, subcutaneous; PWV, pulse wave velocity
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terol, TG and HDL cholesterol concentrations did not
change frombaseline in either group at 16weeks. After 16
weeks exercise there was a significant within-group de-
crease (P .03) in plasma LDL cholesterol concentration.
NEFAconcentrationdidnot change in either group.How-
ever adipose tissue IR decreased by 24  10% in the ex-
ercise group (P .03) with no change in controls (change
between groups, P  .02). After 16 weeks there was no
significant change in VLDL1-TG or VLDL1 apoB con-
centration in either group. However VLDL2 TG, choles-
terol and apoB concentration were reduced (P .01, P
.02, P  .04) in the exercise group with no change in
controls. The particle size of VLDL1 (TG/apoB) was re-
duced in the exercise group (P  .03), and was different
between groups (P  .04).
VLDL1- and VLDL2- TG kinetics (Table 3, Figure 2)
At baseline VLDL1 and VLDL2-TG kinetics did not
differ between groups. After 16 weeks VLDL1-TG FCR
was increased in the exercise group (P  .05) due to an
increase in the VLDL1-TG catabolism FCR (P .05). The
percent change in IHCL in all participants was negatively
correlatedwith the change in VLDL1-TG catabolism FCR
(r-0.74, P  .001) (Figure 2) and positively correlated
with the change inVLDL1-TG transfer FCR (r0.63,P
.001). There was no change in VLDL2-TG FCR,
VLDL1-TG PR, VLDL2-TG PR and total VLDL-TG PR
within or between groups.
Figure 1. VO2max at 0 and 16 weeks in a) Exercise group and b)
Control group
Table 3. VLDL TG kinetics (mean  SEM)
Pre Ex
n  15
Post Ex
n  15
Within
group P
Pre Control
n  12
Post Control
n  12
Within
group P
Between
group P
VLDL1-TG mmol/liter 1.24  0.15 1.04  0.11 NS 1.00  0.12 1.05  0.15 NS NS
VLDL2-TG mmol/liter 0.17  0.02 0.11  0.01 <0.01 0.13  0.02 0.14  0.02 NS 0.01
VLDL-TG mmol/liter 1.41  0.17 1.15  0.11 <0.01 1.13  0.15 1.19  0.16 NS 0.08
VLDL1 -Chol mmol/liter 0.31  0.04 0.29  0.04 NS 0.29  0.04 0.32  0.05 NS NS
VLDL2-Chol mmol/liter 0.10  0.07 0.07  0.01 <0.02 0.09  0.03 0.09  0.02 NS <0.01
VLDL-Chol mmol/liter 0.41  0.04 0.36  0.04 0.02 0.38  0.06 0.40  0.06 NS 0.01
VLDL1-TG FCR pools/d* 8.25  1.07 9.80  1.51 <0.05 9.09  0.80 8.62  1.02 NS 0.06
VLDL1-TG catabolism FCR pools/day** 6.82  1.16 8.14  1.31 0.05 7.46  0.78 5.92  0.53 NS 0.02
VLDL1-TG transfer FCR pools/day** 1.22  0.16 1.44  0.38 NS 1.63  0.48 2.71  1.35 NS NS
VLDL1-TG PR mg/kg/d* 230.9  20.3 232.5  12.9 NS 218.4  30.6 213.9  24.1 NS NS
VLDL2-TG FCR pools/d** 10.44  0.70 11.62  1.48 NS 12.05  1.52 13.16  3.18 NS NS
VLDL2-TG PR mg/kg/d** 40.7  4.6 33.9  5.1 NS 37.6  5.5 49.6  10.7 NS NS
VLDL2-TG hepatic PR mg/kg/d** 5.03  0.83 4.23  0.93 NS 6.7  1.3 8.3  3.1 NS NS
VLDL-TG PR mg/kg/d** 235.6  20.2 236.4  13.0 NS 225.1  30.4 222.3  25.5 NS NS
VLDL1 to VLDL2-TG transfer mg/kg/d** 35.7  4.7 29.7  4.6 NS 30.9  4.8 41.3  8.5 NS NS
*n  13 and **n  12 in exercise group due to problems with sample analysis
Table 4. VLDL apoB kinetics (meanSEM)
Pre Ex
n  15
Post Ex
n  15
Within group
p value
Pre Control
n  12
Post Control
n  12
Within group
p value
Between-group
p value
VLDL1 apoB concentration mg/liter 18.4  2.2 20.2  2.8 NS 16.7  1.5 17.3  2.3 NS NS
VLDL2 -apoB concentration mg/liter 12.9  1.4 9.7  1.0 0.04 11.2  1.8 11.1  1.1 NS NS
VLDL1--TG/V1apoB 66.2  7.0 49.8  4.0 0.03 56.5  7.2 60.12  8.7 NS 0.04
VLDL2--TG/V2apoB 12.9  1.5 11.6  1.1 NS 12.1  1.4 14.8  3.5 NS NS
VLDL1-apoB FCR pools/day 7.18  0.57 10.93  1.49 0.02 10.91  1.76 8.88  1.06 NS 0.01
VLDL1-apoB catabolism FCR pools/day 5.98  0.66 10.39  1.49 <0.01 9.87  1.86 7.89  1.23 NS 0.01
VLDL1 --apoB transfer FCR pools/day 1.19  0.16 0.54  0.1 0.005 1.04  0.25 0.99  0.3 NS 0.06
VLDL2 --apoB FCR pools/day 12.3  1.3 11.8  1.3 NS 16.9  3.0 12.9  1.8 NS NS
VLDL1-apoB PR mg/kg/d 3.67  0.65 5.54  0.49 0.003 4.92  0.80 3.96  0.60 NS 0.006
VLDL2-apoB PR mg/kg/d 4.05  0.42 3.22  0.44 NS 4.93  1.00 3.98  0.60 NS NS
VLDL2-apoB hepatic PR mg/kg/d 0.52  0.09 0.50  0.10 NS 0.74  0.23 0.89  0.24 NS NS
VLDL1- to VLDL2 transfer mg/kg/d 3.52  0.04 2.72  0.01 NS 4.19  1.09 3.09  0.69 NS 0.013
VLDL apoB PR mg/kg/d 4.19  0.66 6.04  0.50 0.004 5.66  0.95 4.85  0.49 NS 0.02
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VLDL1- and VLDL2 ApoB kinetics (Table 4, Figure 2)
VLDL1- andVLDL2-apoBkineticswere not different at
baseline between groups. VLDL1-apoB FCR was in-
creased at 16 weeks in the exercise group (P  .02) with
no change in controls (between groups,P .01). Thiswas
due to a increase in the catabolismFCR (P .01)while the
transfer FCR (toVLDL2)was decreased (P .005). There
wasnochange inVLDL2-apoBFCR.VLDL1-apoBPRand
Figure 2. a) VLDL1 (V1) apoB FCR, b) VLDL1-TG FCR c) VLDL1-apoB production rate and d) VLDL1-TG production rate, at 0 weeks (solid bar) and
16 weeks (hatched bar) in the exercise and control groups, e) relationship between percent change in IHCL and the change in VLDL1-apoB
production rate and f) relationship between percent change in IHCL and the change in VLDL1-TG catabolism FCR. Black circles: exercise group;
open circles: control group.
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total VLDL-apoB PR increased in the exercise group (P
.003, P .004) (between groups P .006, P .02). The
percent change in IHCL between 0 and 16 weeks in all
participants correlated negatively with the change in
VLDL1-apoB PR (r-0.48, P  .01) (Figure 2).
Discussion
We have demonstrated for the first time that a 16 week
supervised exercise intervention which significantly im-
proved cardiorespiratory fitness and reduced liver fat by
over 50% inmenwithNAFLD increased the FCR (amea-
sure of clearance) of both VLDL1-TG and apoB.
It is well documented that VLDL1-TG and apoB FCR
increases with acute exercise (24) but this effect is not
sustained 48h after exercise (25). In the current study sub-
jects abstained from exercise for 72h prior to the mea-
surement of VLDL kinetics in order to measure the
chronic, rather than the acute, effects of exercise. NAFLD
is highly associated with peripheral and hepatic insulin
resistance (26, 27), as observed in our participants who
had a fasting insulin concentration double that reported in
healthy subjects. There was an improvement in insulin
sensitivity, as measured by HOMA %S, with exercise
training, as has also been demonstrated previously in type
2 diabetes mellitus and overweight subjects (20, 15). We
have also shown in a different subset of patients with NA-
FLD that 4 months of exercise training (with a similar-
sized effect on fitness and IHCL to the current study) im-
proved peripheral but not hepatic insulin sensitivity (16).
In the current study an improvement in peripheral insulin
sensitivity was also demonstrated with the decrease in ad-
ipose-IR. LPL activity is regulated by insulin (28) and 20-
weeks endurance exercise training in healthy men, which
increased VO2max by 13%, has previously been shown to
significantly increase postheparin plasma lipoprotein
lipase (29). Increased LPL activity would provide a mech-
anism for the increase in VLDL1-TG and apoB FCR ob-
served in the current study. Notably for VLDL1-TG and
apoBFCR itwas the catabolic pathway thatwas increased
rather than the transfer of TG to VLDL2. The increased
clearance of TG from the systemic circulation, while the
production rate of TG was simultaneously maintained,
would enable the liver to export some of the stored TG for
hydrolysis in skeletal muscle to sustain increased demand
for fatty acids during exercise.
The reduction in body weight in the exercise group is
unlikely to have mediated the increase in VLDL1-TG and
apoB clearance since previous studies have shown weight
loss in obese men, following a low calorie diet, reduces
VLDL-apoB production rate with no effect on VLDL-
apoB FCR (30). Similarly in obese women, a hypocaloric
diet has been shown to have no effect on either VLDL-TG
or VLDL-apoB FCR (31).
The failure of exercise training to lower VLDL1-apoB
andTGproduction rate and to increaseVLDL1-apoBpro-
duction rate was unexpected. This differs from a study in
patients with type 2 diabetes where exercise training for 6
months, resulting in a 16% increase in VO2max, reduced
VLDL-apoB production rate (20). Liver fat was not mea-
sured in the latter study, patients were on oral hypogly-
cemic treatment (metformin and sulfonylureas) and some
of the participants were African-Caribbean, a group
known to have a lower propensity for NAFLD (32). The
increase in VLDL1-apoB production rate following exer-
cise training in the current study may be explained by the
marked decrease in fasting insulin concentration in re-
sponse to the improved peripheral insulin sensitivity,
while at the same timehepatic insulin resistancewasmain-
tained. Insulin regulates VLDL assembly (6, 7, 8), thus a
lowering of insulinwill increase apoB secretion. It has also
been shown in mice that triglycerides can rescue apoB
from posttranslational degradation (33). The up-regula-
tion of VLDL1-apoB production rate in response to exer-
cise training could increase TG export and therefore assist
in the reduction of liver fat. This could also explain the
maintenanceofplasmaTGlevels despite adecrease in liver
fat.
The findings of this study differ from a previous study
of patients withNAFLDwhere 16weeks exercise training
at an exercise intensity comparable to the current study
had no effect on VLDL-TG and apoB kinetics (14). The
discordant findings most likely reflect a greater improve-
ment in both cardiorespiratory fitness and thus a greater
reduction in IHCL in our study participants. VO2max in-
creased by 31% in the current study compared to only a
9% increase in the previous study (14). An alternative or
additional explanation is that total VLDL-TG and apoB
(sf 20–400) were measured in the previous study, rather
than VLDL1 and VLDL2 as in the current study. There is
evidence that VLDL1 and VLDL2 are independently reg-
ulated (5) and that exercise primarily affects VLDL1 ki-
netics (34), and so the effect of exercise onVLDL1maynot
be revealed by measurements on total VLDL. VLDL1 car-
riesmoreTGcompared toVLDL2perparticle andLPLhas
been showntohaveapreference forTG-richparticles (35).
In NAFLD, CV events are the most common cause of
mortality (36). Both the FRS, which has been shown to
accurately predict the actual 10-year CV disease risk in
patients with NAFLD (37), and arterial stiffness, an indi-
cator of CVD and independent predictor of the corre-
sponding risk and LDL cholesterol were decreased fol-
lowing exercise training. The reduced LDL cholesterol
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may be related to the small weight loss (38). These mea-
sures demonstrate that 16 weeks exercise training can re-
duce CVD risk in NAFLD.
The correlation between liver fat and cardiorespiratory
fitness suggests the latter is the main driver for reduced
IHCL in the exercise group.However the smallweight loss
in the exercise group will have contributed to the reduc-
tion in IHCL (11). Both endurance and resistance exercise
with and without weight loss have been shown to reduce
liver fat (39). The decrease in IHCL following exercisewas
not accompanied by any change in IMCL. This has also
been reported inaprevious exercise study inobese subjects
(13). A recent meta-analysis of 33 studies examining the
effect of lifestyle interventions on ectopic fat deposition in
overweight andobese adults showedonly a nonsignificant
trend toward reductions in IMCL (40). Although the
meta-analysis suggested pancreatic fat reduced with ex-
ercise, this was not found in the current study. There have
been few studies specifically addressing effects of exercise
intervention on pancreatic fat.
In conclusion, with an exercise intervention in nondi-
abetic men with NAFLD that significantly improved fit-
ness and cardio-metabolic health, and produced a signif-
icant reduction in IHCL, the liver continued to export
excessive amounts of TG in VLDL. This may reflect the
failure to normalize IHCL and restore hepatic insulin sen-
sitivity. A longer duration or higher intensity exercise in-
tervention, or a combined approach with calorie restric-
tion, may be required to achieve this and to lower plasma
TG and VLDL production rate.
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